Welcome to our dedicated page for Claritev news (Ticker: CTEV), a resource for investors and traders seeking the latest updates and insights on Claritev stock.
Claritev Corporation reports developments for a healthcare technology, data and insights company serving the U.S. healthcare system. The company provides technology-enabled solutions built on claims expertise, advanced analytics and AI to support affordability, price transparency, payment integrity, network optimization and benefits design for payers, employers, patients, providers and third parties.
Recurring news includes quarterly results, guidance, investor-day strategy, conference participation, AI-focused leadership and workflow updates, product-roadmap themes and Claritev Cares community initiatives. Company updates often connect its analytics platform with healthcare cost management, revenue integrity and vertical-market expansion.
ClearNote Health has announced a new agreement with Claritev (NYSE: CTEV) to make its Avantect® Pancreatic Cancer Test available through Claritev's national PHCS and MultiPlan Networks. The test is a DNA-based blood screening that combines epigenomic and genomic signals with machine learning to detect early pancreatic cancer indicators.
The Avantect test specifically targets high-risk patients, including:
- Type 2 diabetes patients aged 50 and older
- Individuals with relevant family history
- People with genetic predisposition
The test utilizes 5-hydroxymethylcytosine (5hmC) profiling in cell-free DNA and AI algorithms to detect tumor development earlier than conventional methods. This is particularly significant as pancreatic cancer often has only a 3% five-year survival rate when diagnosed at advanced stages.